You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.
Scientists from the UK and China discussed two new NIPTs that include single-gene disorders and a study to estimate disease recurrence risk in families.
The partners are planning to integrate the technology into Horizon's research tools and services and to develop it for applications in cell therapeutics.
The Telegraph reports that UK regulators gave CRISPR Therapeutics the go-ahead for its beta thalassemia clinical trial.
CRISPR Therapeutics is moving toward clinical trials for beta thalassemia and sickle cell disease treatments, according to Wired.
The researchers plan to use the method in clinical research, designing noninvasive prenatal tests for single-gene disorders like beta thalassemia.
Using base editing, a Chinese research team has repaired a β-thalassemia-causing mutation in cloned embryos, Nature News reports.
In PNAS this week: work toward a CRISPR/Cas9-based approach to treat beta-thalassemia or sickle cell disease, bacteriophages uncovered in human stool, and more.
In Nature this week: Exome Aggregation Consortium analysis of some 60,000 exomes, and more.
Scientists introduced an indel to a promoter region to mimic a benign, naturally-occurring mutation that activated fetal hemoglobin production.
UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.
The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.
President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.
In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.